Clinical trial
Comparison of the Safety and Successful Ablation of Thyroid Remnant in…
NCT00196729 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00196729 |
|---|---|
| Title | Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration |
| Official title | A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thyroid Neoplasms |
| Intervention type | Drug |
| Interventions | Thyrogen + Radioiodine (131I) |
| Enrollment | 63 |
| Start date | Dec 1, 2001 |
| Completion | Sep 1, 2003 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 18, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: